These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21350573)

  • 1. Comment on 'Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial'.
    Fayers T
    Eye (Lond); 2011 Jun; 25(6):820; author reply 820. PubMed ID: 21350573
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial.
    Subramanian ML; Abedi G; Ness S; Ahmed E; Fenberg M; Daly MK; Houranieh A; Feinberg EB
    Eye (Lond); 2010 Nov; 24(11):1708-15. PubMed ID: 20885427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
    Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Age-related macular degeneration: therapeutic hopes].
    Behar-Cohen F; Sennlaub F; Berdugo M
    Med Sci (Paris); 2007 Feb; 23(2):127-9. PubMed ID: 17291419
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of neovascular age-related macular degeneration with bevacizumab].
    Monzón Moreno A
    Farm Hosp; 2006; 30(6):387-8. PubMed ID: 17298199
    [No Abstract]   [Full Text] [Related]  

  • 6. Saving money on the PBS: ranibizumab or bevacizumab for neovascular macular degeneration?
    Harvey KJ; Day RO; Campbell WG; Lipworth W
    Med J Aust; 2011 Jun; 194(11):567-8. PubMed ID: 21644867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Donahue SP; Recchia F; Sternberg P
    Am J Ophthalmol; 2010 Aug; 150(2):287; author reply 287. PubMed ID: 20670740
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer drug offers effective, cheaper option for AMD.
    Stephenson J
    JAMA; 2011 May; 305(20):2053-4. PubMed ID: 21610231
    [No Abstract]   [Full Text] [Related]  

  • 9. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab.
    Mitchell P
    Curr Med Res Opin; 2011 Jul; 27(7):1465-75. PubMed ID: 21623685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bevacizumab or ranibizumab, or the tale of Robin Hood and King Richard Lion Heart].
    Monés J
    Arch Soc Esp Oftalmol; 2007 Sep; 82(9):529-30. PubMed ID: 17846939
    [No Abstract]   [Full Text] [Related]  

  • 11. Good news about new macular degeneration drugs.
    Harv Health Lett; 2011 Jan; 36(3):7. PubMed ID: 21341413
    [No Abstract]   [Full Text] [Related]  

  • 12. Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery.
    Harris MJ
    BMJ; 2010 Jul; 341():c3718. PubMed ID: 20627986
    [No Abstract]   [Full Text] [Related]  

  • 13. Study aims to clarify efficacy, safety of eye drug treatments.
    Mitka M
    JAMA; 2007 Apr; 297(14):1538-9. PubMed ID: 17426265
    [No Abstract]   [Full Text] [Related]  

  • 14. New treatments for age-related macular degeneration.
    Avery RL
    Lancet; 2007 Oct; 370(9597):1479-80; author reply 1480. PubMed ID: 17964341
    [No Abstract]   [Full Text] [Related]  

  • 15. Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?
    Ziemssen F; Grisanti S; Bartz-Schmidt KU; Spitzer MS
    Drugs Aging; 2009; 26(4):295-320. PubMed ID: 19476398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
    Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
    Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The current state and issues of medical treatment for age-related macular degeneration].
    Ishida S
    Nihon Yakurigaku Zasshi; 2008 Jan; 131(1):47-9. PubMed ID: 18187884
    [No Abstract]   [Full Text] [Related]  

  • 18. Macular degeneration, patients' groups, and pharma.
    The Lancet
    Lancet; 2007 Jul; 370(9583):194. PubMed ID: 17658373
    [No Abstract]   [Full Text] [Related]  

  • 19. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study.
    Tufail A; Patel PJ; Egan C; Hykin P; da Cruz L; Gregor Z; Dowler J; Majid MA; Bailey C; Mohamed Q; Johnston R; Bunce C; Xing W;
    BMJ; 2010 Jun; 340():c2459. PubMed ID: 20538634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab and ranibizumab. A matter of public interest.
    Garattini S; Bertele' V
    BMJ; 2010 Jul; 341():c3721. PubMed ID: 20627987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.